Chlamydophila pneumoniae infection and cardiovascular disease

North American Journal of Medical Sciences

Volumn 5, Issue 3, 2013, Pages 169-181

  Joshi, Rajnish ^a   Khandelwal, Bidita ^a   Joshi, Deei ^a   Gua, Om Prakash ^b  

^a SIKKIM MANIPAL INSTITUTE OF MEDICAL SCIENCES   (India)

^b MAHATMA GANDHI INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Atherosclerosis; Cardiovascular disease; Chlamydophila pneumonia; Infection

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BACTERIAL DNA; CLARITHROMYCIN; GATIFLOXACIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; ROXITHROMYCIN;

ANGIOGRAPHY; ANTIBIOTIC THERAPY; APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR MORTALITY; CASE CONTROL STUDY; CHLAMYDIAL PNEUMONIA; CROSS REACTION; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DRUG MEGADOSE; ELECTRON MICROSCOPY; FOLLOW UP; HUMAN; HYPOTHESIS; IMMUNOFLUORESCENCE TEST; META ANALYSIS (TOPIC); POLYMERASE CHAIN REACTION; PREVALENCE; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; REVIEW; SEROLOGY; SYSTEMATIC REVIEW (TOPIC);

EID: 84875335403     PISSN: 22501541     EISSN: 19472714     Source Type: Journal    
DOI: 10.4103/1947-2714.109178     Document Type: Review

References (108)

1. Murray JL, Lopez AD. Global mortality, disability, and contribution of risk factors: Global burden of disease study. Lancet 1997;349:1436-42.
2. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004;364:937-52.
3. Broxmeyer L. Heart disease: The greatest 'risk' factor of them all. Med Hypotheses 2004;62:773-9.
4. Boman J, Hammerschlag MR. Chlamydia pneumoniae and atherosclerosis: Critical assessment of diagnostic methods and relevance to treatment studies. Clin Microbiol Rev 2002;15:1-20.
5. Grayston JT. Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J Infect Dis 2000;181 Suppl 3:S402-10.
6. Mahony JB, Coombes BK. Chlamydia pneumoniae and atherosclerosis: Does the evidence support a causal or contributory role? FEMS Microbiol Lett 2001;197:1-9.
7. Rosenfeld ME, Campbell LA. Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thromb Haemost. 2011;106:858-67.
8. Erkkila L, Laitinen K, Haasio K, Tiirola T, Jauhiainen M, Lehr HA, et al. Heat shock protein 60 autoimmunity and early lipid lesions in cholesterol-fed C57BL/6JBom mice during Chlamydia pneumoniae infection. Atherosclerosis 2004;177:321-8.
9. Ramirez JA. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group. Ann Intern Med 1996;125:979-82.
10. Apfalter P, Loidl M, Nadrchal R, Makristathis A, Rotter M, Bergmann M, et al. Isolation and continuous growth of Chlamydia pneumoniae from arterectomy specimens. Eur J Clin Microbiol Infect Dis 2000;19:305-8.
11. Jackson LA, Campbell LA, Kuo CC, Rodriguez DI, Lee A, Grayston JT. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis 1997;176:292-5.
12. Kuo CC, Gown AM, Benditt EP, Grayston JT. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb 1993;13:1501-4.
13. Sessa R, Di Pietro M, Schiavoni G, Galdiero M, Cipriani P, Romano S, et al. Chlamydia pneumoniae in asymptomatic carotid atherosclerosis. Int J Immunopathol Pharmacol 2006;19:111-8.
14. Kuo CC, Coulson AS, Campbell LA, Cappuccio AL, Lawrence RD, Wang SP, et al. Detection of Chlamydia pneumoniae in atherosclerotic plaques in the walls of arteries of lower extremities from patients undergoing bypass operation for arterial obstruction. J Vasc Surg 1997;26:29-31.
15. Ieven MM, Hoymans VY. Involvement of Chlamydia pneumoniae in atherosclerosis: More evidence for lack of evidence. J Clin Microbiol 2005;43:19-24.
16. Liu C, Waters DD. Chlamydia pneumoniae and atherosclerosis: from Koch postulates to clinical trials. Prog Cardiovasc Dis 2005;47:230-9.
17. Shor A, Phillips JI. Chlamydia pneumoniae and atherosclerosis. JAMA 1999;282:2071-3.
18. Hu H, Pierce GN, Zhong G. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 1999;103:747-53.
19. Epstein SE, Zhu J, Najafi AH, Burnett MH. Insights Into the Role of Infection in Atherogenesis and in Plaque Rupture. Circulation 2009;119:3133-41.
20. Bloemenkamp DG, Mali WP, Visseren FL, van der Graaf Y. Meta-analysis of sero-epidemiologic studies of the relation between Chlamydia pneumoniae and atherosclerosis: Does study design influence results? Am Heart J 2003;145:409-17.
21. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997;350:430.
22. Toss H, Gnarpe J, Gnarpe H, Siegbahn A, Lindahl B, Wallentin L. Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease. Eur Heart J 1998;19:570-7.
23. Korner I, Blatz R, Wittig I, Pfeiffer D, Ruhlmann C. Serological evidence of Chlamydia pneumoniae lipopolysaccharide antibodies in atherosclerosis of various vascular regions. Vasa 1999;28:259-63.
24. Gnarpe J, Sparr A, Naas J, Lundback A. Serological analysis of specific IgA to Chlamydia pneumoniae: Increased sensitivity of IgA antibody detection using prolonged incubation and high antigen concentration. APMIS 2000;108:357-62.
25. Strachan DP, Carrington D, Mendall MA, Ballam L, Morris J, Butland BK, et al. Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the caerphilly prospective heart disease study. BMJ 1999;318:1035-9.
26. Shimada K, Daida H, Mokuno H, Watanabe Y, Sawano M, Iwama Y, et al. Association of seropositivity for antibody to Chlamydia-specific lipopolysaccharide and coronary artery disease in Japanese men. Jpn Circ J 2001;65:182-7.
27. Kinjo K, Sato H, Ohnishi Y, Hishida E, Nakatani D, Mizuno H, et al. Joint effects of Chlamydia pneumoniae infection and classic coronary risk factors on risk of acute myocardial infarction. Am Heart J 2003;146:324-30.
28. Voorend M, Faber CG, van der Ven AJ, Kessels F, Bruggeman CA, Lodder J. Chlamydia pneumoniae is a likely risk factor for ischemic stroke in young patients. J Stroke Cerebrovasc Dis 2004;13:85-91.
29. Piechowski-Jozwiak B, Mickielewicz A, Gaciong Z, Berent H, Kwiecinski H. Elevated levels of anti-Chlamydia pneumoniae IgA and IgG antibodies in young adults with ischemic stroke. Acta Neurol Scand 2007;116:144-9.
30. Ossewaarde JM, Feskens EJ, De Vries A, Vallinga CE, Kromhout D. Chlamydia pneumoniae is a risk factor for coronary heart disease in symptom-free elderly men, but Helicobacter pylori and cytomegalovirus are not. Epidemiol Infect 1998;120:93-9.
31. Roivainen M, Viik-Kajander M, Palosuo T, Toivaen P, Leionen M, Saikku P, et al. Infections, inflammation and the risk of Coronary heart disease. Circulation 2000;101:252-7.
32. Smieja M, Mahony J, Petrich A, Boman J, Chernesky M. Association of circulating Chamydia pneumonia DNA with cardiovascular disease A systematic review. BMC Infect Dis 2003;2:21.
33. Podsiadly E, Przyluski J, Kwiatkowski A, Kruk M, Wszola M, Nosek R, et al. Presence of Chlamydia pneumoniae in patients with and without atherosclerosis. Eur J Clin Microbiol Infect Dis 2005;24:507-13.
34. Mitusch R, Luedemann J, Wood WG, Berger K, Schminke U, Suter M, et al. Asymptomatic carotid atherosclerosis is associated with circulating chlamydia pneumoniae DNA in younger normotensive subjects in a general population survey. Arterioscler Thromb Vasc Biol 2005;25:386-91.
35. Tsirpanlis G, Chatzipanagiotou S, Ioannidis A, Moutafis S, Poulopoulou C, Nicolaou C. Detection of Chlamydia pneumoniae in peripheral blood mononuclear cells: Correlation with inflammation and atherosclerosis in haemodialysis patients. Nephrol Dial Transplant 2003;18:918-23.
36. Wang SS, Tondella ML, Bajpai A, Mathew AG, Mehranpour P, Li W, et al. Circulating Chlamydia pneumoniae DNA and advanced coronary artery disease. Int J Cardiol 2007;118:215-9.
37. Yamaguchi H, Yamada M, Uruma T, Kanamori M, Goto H, Yamamoto Y, et al. Prevalence of viable Chlamydia pneumoniae in peripheral blood mononuclear cells of healthy blood donors. Transfusion 2004;44:1072-8.
38. Atik B, Johnston SC, Dean D. Association of carotid plaque Lp-PLA (2) with macrophages and Chlamydia pneumoniae infection among patients at risk for stroke. PLoS One 2010;5:e11026.
39. Lysenko AI, Solov'eva NA. The implication of Chlamydia pneumoniae in damage to human aortic endotheliocytes in atherosclerosis. Arkh Patol 2010;72:21-5.
40. Benagiano M, Munari F, Ciervo A, Amedei A, Paccani SR, Mancini F, et al. Chlamydophila pneumoniae phospholipase D (CpPLD) drives Th17 inflammation in human atherosclerosis. Proc Natl Acad Sci U S A 2012;109:1222-7.
41. Jha HC, Srivastava P, Prasad J, Mittal A. Chlamydia pneumoniae heat shock protein 60 enhances expression of ERK, TLR-4 and IL-8 in atheromatous plaques of coronary artery disease patients. Immunol Invest 2011;40:206-22.
42. Buss C, Opitz B, Hocke AC, Lippmann J, van Laak V, Hippenstiel S, et al. Essential role of mitochondrial antiviral signaling, IFN regulatory factor (IRF) 3, and IRF7 in Chlamydophila pneumoniae-mediated IFN-beta response and control of bacterial replication in human endothelial cells. J Immunol 2010;184:3072-8.
43. Prochnau D, Rodel J, Prager K, Kuersten D, Heller R, Straube E, et al. Induced expression of lectin-like oxidized ldl receptor-1 in vascular smooth muscle cells following Chlamydia pneumoniae infection and its down-regulation by fluvastatin. Acta Microbiol Immunol Hung 2010;57:147-55.
44. Yoshida T, Koide N, Mori I, Ito H, Yokochi T. Chlamydia pneumoniae infection enhances lectin-like oxidized low-density lipoprotein receptor (LOX-1) expression on human endothelial cells. FEMS Microbiol Lett 2006;260:17-22.
45. Bennermo M, Nordin M, Lundman P, Boqvist S, Held C, Samnegard A, et al. Genetic and environmental influences on the plasma interleukin-6 concentration in patients with a recent myocardial infarction: A case-control study. J Interferon Cytokine Res 2011;31:259-64.
46. Brykczynski M, Zych A, Goracy I, Maczynska I, Wojciechowska-Koszko I, Mokrzycki K, et al. Evaluation of the level of antibodies against Chlamydophila (Chlamydia) pneumoniae in post-surgery heart ischaemia patients and their clinical conditions-a six-year study. Arch Med Sci 2010;6 (2):214-20.
47. Reverter JL, Tassies D, Alonso N, Pellitero S, Sanmarti A, Reverter JC. Non-detectable Chlamydophila pneumoniae DNA in peripheral leukocytes in type 2 diabetes mellitus patients with and without carotid atherosclerosis. Med Clin (Barc) 2012;138:11-4.
48. Tremolada S, Delbue S, Ferraresso M, Carloni C, Elia F, Larocca S, et al. Search for genomic sequences of microbial agents in atherosclerotic plaques. Int J Immunopathol Pharmacol 2011;24:243-6.
49. Andraws R, Berger JS, Brown DL. Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA 2005;293:2641-7.
50. Dowell SF, Peeling RW, Boman J, Carlone GM, Fields BS, Guarner MR, et al. Standardizing Chlamydia pneumoniae assays: reccomendations from the Centers for Disease Control and prevention (USA) and Laboratory center for disease control (Canada). Clin Infect Dis 2001;33:492-503.
51. Apfalter P. Chlamydia pneumoniae, stroke, and serological associations: Anything learned from the atherosclerosis-cardiovascular literature or do we have to start over again? Stroke 2006;37:756-8.
52. Rothman KJ, Poole C. A strengthening program for weak associations. Int J Epidemiol 1988;17:955.
53. Deniset JF, Pierce GN. Possibilities for therapeutic interventions in disrupting Chlamydophila pneumoniae involvement in atherosclerosis. Fundam Clin Pharmacol 2010;24:607-17.
54. Blasi F, Cosentini R, Raccanelli R, Massari FM, Arosio C, Tarsia P, et al. A possible association of Chlamydia pneumoniae infection and acute myocardial infarction in patients younger than 65 years of age. Chest 1997;112:309-12.
55. Thomas GN, Scheel O, Koehler AP, Bassett DC, Cheng AF. Respiratory Chlamydial infections in a Hong Kong teaching hospital and association with coronary heart disease. Scand J Infect Dis Suppl 1997;104:30-3.
56. Gabriel AS, Gnarpe H, Gnarpe J, Hallander H, Nyquist O, Martinsson A. The prevalence of chronic Chlamydia pneumoniae infection as detected by polymerase chain reaction in pharyngeal samples from patients with ischaemic heart disease. Eur Heart J 1998;19:1321-7.
57. Boman J. High prevalence of Chlamydia Pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in patients with middle aged blood donors. J Infect Dis 1998;178:274-7.
58. Mazzoli S, Tofani N, Fantini A, Semplici F, Bandini F, Salvi A, et al. Chlamydia pneumoniae antibody response in patients with acute myocardial infarction and their follow-up. Am Heart J 1998;135:15-20.
59. Cook PJ, Honeybourne D, Lip GY, Beevers DG, Wise R, Davies P. Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia: The West Birmingham Stroke Project. Stroke 1998;29:404-10.
60. Anderson JL, Carlquist JF, Muhlestein JB, Horne BD, Elmer SP. Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol 1998;32:35-41.
61. Miyashita N, Toyota E, Sawayama T, Matsumoto A, Mikami Y, Kawai N, et al. Association of chronic infection of Chlamydia pneumoniae and coronary heart disease in the Japanese. Intern Med 1998;37:913-6.
62. Cellesi C, Sansoni A, Casini S, Migliorini L, Zacchini F, Gasparini R, et al. Chlamydia pneumoniae antibodies and angiographically demonstrated coronary artery disease in a sample population from Italy. Atherosclerosis 1999;145:81-5.
63. Shimada K, Mokuno H, Watanabe Y, Sawano M, Sato H, Kurata T, et al. Association between chlamydial infection and coronary artery disease. J Cardiol 1999;34:259-65.
64. Sessa R, Di Pietro M, Santino I, del Piano M, Varveri A, Dagianti A, et al. Chlamydia pneumoniae infection and atherosclerotic coronary disease. Am Heart J 1999;137:1116-9.
65. Abdelmouttaleb I, Danchin N, Ilardo C, Aimone-Gastin I, Angioi M, Lozniewski A, et al. C-Reactive protein and coronary artery disease: Additional evidence of the implication of an inflammatory process in acute coronary syndromes. Am Heart J 1999;137:346-51.
66. Altman R, Rouvier J, Scazziota A, Absi RS, Gonzalez C. Lack of association between prior infection with Chlamydia pneumoniae and acute or chronic coronary artery disease. Clin Cardiol 1999;22:85-90.
67. Leowattana W, Mahanonda N, Bhuripunyo K, Leelarasamee A, Pokum S, Suwimol B. The prevalence of Chlamydia pneumoniae antibodies in Thai patients with coronary artery disease. J Med Assoc Thai 1999;82:792-7.
68. Kaykov E, Abbou B, Friedstrom S, Hermoni D, Roguin N. Chlamydia preumoniae in ischemic heart disease. Isr Med Assoc J 1999;1:225-7.
69. Nobel M, De Torrente A, Peter O, Genne D. No serological evidence of association between chlamydia pneumonia infection and acute coronary heart disease. Scand J Infect Dis 1999;31:261-4.
70. Kontula K, Vuorio A, Turtola H, Saikku P. Association of seropositivity for Chlamydia pneumoniae and coronary artery disease in heterozygous familial hypercholesterolaemia. Lancet 1999;354:46-7.
71. Elkind MS, Lin IF, Grayston JT, Sacco RL. Chlamydia pneumoniae and the risk of first ischemic stroke: The Northern Manhattan Stroke Study. Stroke 2000;31:1521-5.
72. Romeo F, Martuscelli E, Chirieolo G, Cerabino LM, Ericson K, Saldeen TG, et al. Seropositivity against Chlamydia pneumoniae in patients with coronary atherosclerosis. Clin Cardiol 2000;23:327-30.
73. Glader CA, Boman J, Saikku P, Stenlund H, Weinehall L, Hallmanns G, et al. The proatherogenic properties of lipoprotein (a) may be enhanced through the formation of circulating immune complexes containing Chlamydia pneumoniae-specific IgG antibodies. Eur Heart J 2000;21:639-46.
74. Hoffmeister A, Rothenbacher D, Wanner P, Bode G, Persson K, Brenner H, et al. Seropositivity to chlamydial lipopolysaccharide and Chlamydia pneumoniae, systemic inflammation and stable coronary artery disease: Negative results of a case-control study. J Am Coll Cardiol 2000;35:112-8.
75. Ammann P, Marschall S, Kraus M, Schmid L, Angehrn W, Krapf R, et al. Characteristics and prognosis of myocardial infarction in patients with normal coronary arteries. Chest 2000;117:333-8.
76. Jantos CA, Krombach C, Wuppermann FN, Gardemann A, Bepler S, Asslan H, et al. Antibody response to the 60-kDa heat-shock protein of Chlamydia pneumoniae in patients with coronary artery disease. J Infect Dis 2000;181:1700-5.
77. Mendis S, Arseculeratne YM, Withana N, Samitha S. Chlamydia pneumoniae infection and its association with coronary heart disease and cardiovascular risk factors in a sample South Asian population. Int J Cardiol 2001;79:191-6.
78. Bloemenkamp DG, Mali WP, Tanis BC, Rosendaal FR, van den Bosch MA, Kemmeren JM, et al. Chlamydia pneumoniae, Helicobacter pylori and cytomegalovirus infections and the risk of peripheral arterial disease in young women. Atherosclerosis 2002;163:149-56.
79. Hasan ZN. Association of Chlamydia pneumoniae serology and ischemic stroke. South Med J 2011;104:319-21.
80. Rai NK, Choudhary R, Bhatia R, Singh MB, Tripathi M, Prasad K, et al. Chlamydia pneumoniae seropositivity in adults with acute ischemic stroke: A case-control study. Ann Indian Acad Neurol 2011;14:93-7.
81. Miettinen H, Lehto S, Saikku P, Haffner SM, Ronnemaa T, Pyorala K, et al. Association of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetic and non-diabetic subjects in Finland. Eur Heart J 1996;17:682-8.
82. Glader CA, Stegmayr B, Boman J, Stenlund H, Weinehall L, Hallmans G, et al. Chlamydia pneumoniae antibodies and high lipoprotein (a) levels do not predict ischemic cerebral infarctions. Results from a nested case-control study in Northern Sweden. Stroke 1999;30:2013-8.
83. Nieto FJ, Folsom AR, Sorlie PD, Grayston JT, Wang SP, Chambless LE. Chlamydia pneumoniae infection and incident coronary heart disease: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 1999;150:149-56.
84. Fagerberg B, Gnarpe J, Gnarpe H, Agewall S, Wikstrand J. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: A prospective study in middle-aged to elderly men with treated hypertension. Stroke 1999;30:299-305.
85. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. BMJ 2000;321:208-13.
86. Wald NJ, Law MR, Morris JK, Zhou X, Wong Y, Ward ME. Chlamydia pneumoniae infection and mortality from ischaemic heart disease: large prospective study. BMJ 2000;321:204-7.
87. Siscovick DS, Schwartz SM, Corey L, Grayston JT, Ashley R, Wang SP, et al. Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults: the Cardiovascular Health Study. Circulation 2000;102:2335-40.
88. Roivainen M, Viik-Kajander M, Palosuo T, Toivanen P, Leinonen M, Saikku P, et al. Infections, inflammation, and the risk of coronary heart disease. Circulation 2000;101:252-7.
89. Johnsen SP, Overvad K, Ostergaard L, Tjonneland A, Husted SE, Sorensen HT. Chlamydia pneumoniae seropositivity and risk of ischemic stroke: A nested case-control study. Eur J Epidemiol 2005;20:59-65.
90. Volanen I, Jarvisalo MJ, Vainionpaa R, Arffman M, Kallio K, Angle S, et al. Increased aortic intima-media thickness in 11-year-old healthy children with persistent Chlamydia pneumoniae seropositivity. Arterioscler Thromb Vasc Biol 2006;26:649-55.
91. Sakurai-Komada N, Koike KA, Kaku Y, Hiraki M, Cui R, Sankai T, et al. Chlamydia pneumoniae infection was associated with risk of mortality from coronary heart disease in Japanese women but not men: The JACC Study. J Atheroscler Thromb 2010;17:510-6.
92. Maass M, Bartels C, Kruger S, Krause E, Engel PM, Dalhoff K. Endovascular presence of Chlamydia pneumoniae DNA is a generalized phenomenon in atherosclerotic vascular disease. Atherosclerosis 1998;140 Suppl 1:S25-30.
93. Kaul R, Uphoff J, Wiedeman J, Yadlapalli S, Wenman WM. Detection of Chlamydia pneumoniae DNA in CD3+lymphocytes from healthy blood donors and patients with coronary artery disease. Circulation 2000;102:2341-6.
94. Berger M, Schroder B, Daeschlein G, Schneider W, Busjahn A, Buchwalow I, et al. Chlamydia pneumoniae DNA in non-coronary atherosclerotic plaques and circulating leukocytes. J Lab Clin Med 2000;136:194-200.
95. Gupta S, Camm AJ. Chronic infection in the etiology of atherosclerosis--the case for Chlamydia pneumoniae. Clin Cardiol 1997;20:829-36.
96. Muhlestein JB, Anderson JL, Carlquist JF, Salunkhe K, Horne BD, Pearson RR, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 2000;102:1755-60.
97. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J 1999;20:121-7.
98. Neumann F, Kastrati A, Miethke T, Pogatsa-Murray G, Mehilli J, Valina C, et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. Lancet 2001;357:2085-9.
99. Leowattana W, Bhuripanyo K, Singhaviranon L, Akaniroj S, Mahanonda N, Samranthin M, et al. Roxithromycin in prevention of acute coronary syndrome associated with Chlamydia pneumoniae infection: a randomized placebo controlled trial. J Med Assoc Thai 2001;84 Suppl 3:S669-75.
100. Stone AF, Mendall MA, Kaski JC, Edger TM, Risley P, Poloniecki J, et al. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 2002;106:1219-23.
101. Zahn R, Schneider S, Frilling B, Seidl K, Tebbe U, Weber M, et al. Antibiotic therapy after acute myocardial infarction: a prospective randomized study. Circulation 2003;107:1253-9.
102. O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: A randomized controlled trial. JAMA 2003;290:1459-66.
103. Cercek B, Shah PK, Noc M, Zahger D, Zeymer U, Matetzky S, et al. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: A randomised controlled trial. Lancet 2003;361:809-13.
104. Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005;352:1637-45.
105. Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 2005;352:1646-54.
106. Jespersen CM, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helo OH, et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 2006;332:22-7.
107. Litinov D, Mahini H, Garilnabi M. Anti-oxidant and anti-inflammatory role of Paraoxanase I: implication in arteriosclerosis diseases. N Am J Med Sci 2012;4:523.
108. Paul J, Dasgupta S, Ghosh MK. Carotid artery intima media thickness as a surrogate marker of atherosclerosis in patients with Chronic Renal Failure on Hemodialysis. N Am J Med Sci 2012;4:77.